GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Here's Why Moderna (MRNA) Stock is Jumping Today
by Madeleine Johnson
On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
by Zacks Equity Research
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
Pluralsight, Stanley Black Decker, Gilead, Regeneron and GlaxoSmithKline as Zacks Bull and Bear of the Day
by Zacks Equity Research
Pluralsight, Stanley Black Decker, Gilead, Regeneron and GlaxoSmithKline as Zacks Bull and Bear of the Day
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling
by Zacks Equity Research
Mylan (MYL) beats on Q1 earnings but misses on sales.
Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.
Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
Glaxo (GSK) Q1 Earnings Beat on COVID-19-Related Stockpiling
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the first quarter. Strong demand for respiratory drugs and Shingrix along with stockpiling of certain drugs amid COVID-19 drive sales.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
by Sweta Jaiswal, FRM
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Glaxo beats both earnings and sales estimates in the first quarter of 2020. Stock up.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.
Pfizer (PFE) Q1 Earnings Top, Biopharma Gains From Coronavirus
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings. While the coronavirus pandemic hurts sales of some Pfizer medicines, it benefited sales of others, resulting in a net positive benefit on total sales.
Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $42.63, moving +0.31% from the previous trading session.
Is a Beat in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Will Gilead (GILD) Beat Q1 Earnings Despite Coronavirus Mayhem?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance along with updates on experimental coronavirus treatment, when Gilead (GILD) reports first-quarter 2020 results.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the first quarter. Results will provide clarity on the impact of coronavirus on the company's business.
Sanofi (SNY) Q1 Earnings, Sales Grow on Coronavirus-Led Buying
by Zacks Equity Research
Sanofi (SNY) beats estimates for both earnings and sales. Around half of the sales and earnings growth at CER was due to COVID-19 associated patient stockpiling. Stock down.
Factors Setting the Tone for Novartis' (NVS) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with the impact of the coronavirus pandemic on its outlook when Novartis (NVS) reports first-quarter 2020 results.
What's in the Cards for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports first-quarter results.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports first-quarter results.